Cullinan Therapeutics Provides Corporate Update and Reports Third Quarter 2026 Financial Results
Globe Newswire•10/11/2026•07:00 ET
0
Key Highlights
- ➤$313.8 million cash and investments support runway into 2029
- ➤Zipalertinib first-line NDA submission initiated under FDA Real-Time Oncology Review
- ➤CLN-049 potentially registrational Phase 2 study launched in relapsed/refractory AML
- ➤Velinotamig global Phase 1/2 autoimmune cytopenias study initiated
- ➤Third-quarter net loss $49.4 million versus $50.6 million year earlier
Expert Statements
Nadim Ahmed, President and CEO of Cullinan Therapeutics
“Our progress this quarter underscores our ability to execute across a differentiated and rapidly advancing portfolio. In addition to the recent clinical success and regulatory progress of zipalertinib, we have advanced velinotamig into a global study in autoimmune cytopenias and initiated a potentially registrational Phase 2 study of CLN-049 in relapsed and refractory AML”
Nadim Ahmed, President and CEO of Cullinan Therapeutics
“Looking ahead, we remain focused on strengthening our leadership position in the T cell engager space. This December, we will share an update for CLN-978 across our ongoing clinical trials in three autoimmune indications and will share updated data for CLN-049 at the ASH Annual Meeting. With multiple upcoming clinical catalysts and regulatory milestones, coupled with our strong balance sheet, we are well positioned to translate this momentum into meaningful progress for patients and long-term value for shareholders.”
CLN-978 (CD19 TCE) multi-dose regimen data in SLE, RA, and Sjögren’s disease will be shared in December
Velinotamig (BCMA TCE) data presented at ACR Convergence 2026; global Phase 1/2 study in autoimmune cytopenias initiated
Get started
Create a free account to read the full story.